Background: Recurrent glioblastoma multiforme (GBM) is resistant to most therapeutic endeavors, with low response rates and survival rarely exceeding six months. There are no clearly established chemotherapeutic regimens and the aim of treatment is palliation with improvement in the quality of life. Patients and methods: We report an open-label, uncontrolled, multicenter phase II trial of temozolomide in 138 patients (intent-to-treat [ITI] population) with glioblastoma multiforme at first relapse and a Karnofsky performance status (KPS) ≥ 70. One hundred twenty-eight patients were histologically confirmed with GBM or gliosarcoma (GS) by independent central review. Chemotherapy-naïve patients were treated with temozolomide 200 mg/m2/day2/day...
The current standard therapy for newly diagnosed glioblastoma is multimodal, comprising surgical res...
Background: The aim of this study was to assess the efficacy of temozolomide in patients with World ...
Background In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedul...
Background: Recurrent glioblastoma multiforme (GBM) is resistant to most therapeutic endeavors, with...
Background: Recurrent glioblastoma multiforme (GBM) is resistant to most therapeutic endeavors, with...
Background: Recurrent glioblastoma multiforme (GBM) is resistant to most therapeutic endeavors, with...
Objectives: To investigate the efficacy of temozolomide (TMZ) in relationship to progression free su...
Background: Continuous research into new strategies and chemotherapy agents for the treatment of mal...
Background: Continuous research into new strategies and chemotherapy agents for the treatment of mal...
Background: Continuous research into new strategies and chemotherapy agents for the treatment of mal...
BACKGROUND: Continuous research into new strategies and chemotherapy agents for the treatment of mal...
BACKGROUND: In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedu...
BACKGROUND: In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedu...
Background: The current standard for newly diagnosed glioblastoma consists of surgical resection fol...
PURPOSE: Cisplatin and temozolomide (TMZ) are active in glioblastoma multiforme (GBM), with differ...
The current standard therapy for newly diagnosed glioblastoma is multimodal, comprising surgical res...
Background: The aim of this study was to assess the efficacy of temozolomide in patients with World ...
Background In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedul...
Background: Recurrent glioblastoma multiforme (GBM) is resistant to most therapeutic endeavors, with...
Background: Recurrent glioblastoma multiforme (GBM) is resistant to most therapeutic endeavors, with...
Background: Recurrent glioblastoma multiforme (GBM) is resistant to most therapeutic endeavors, with...
Objectives: To investigate the efficacy of temozolomide (TMZ) in relationship to progression free su...
Background: Continuous research into new strategies and chemotherapy agents for the treatment of mal...
Background: Continuous research into new strategies and chemotherapy agents for the treatment of mal...
Background: Continuous research into new strategies and chemotherapy agents for the treatment of mal...
BACKGROUND: Continuous research into new strategies and chemotherapy agents for the treatment of mal...
BACKGROUND: In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedu...
BACKGROUND: In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedu...
Background: The current standard for newly diagnosed glioblastoma consists of surgical resection fol...
PURPOSE: Cisplatin and temozolomide (TMZ) are active in glioblastoma multiforme (GBM), with differ...
The current standard therapy for newly diagnosed glioblastoma is multimodal, comprising surgical res...
Background: The aim of this study was to assess the efficacy of temozolomide in patients with World ...
Background In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedul...